Huangjing Yangji Formula Granules
PreclinicalSmall molecule
Huangjing Yangji Formula Granules is one of 24 small molecule programs targeting Sarcopenia. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
36 competitors in Sarcopenia
#DrugCompanyPhaseTrials
1Evrenzo
AstellasApproved
Calciferol
Alnylam PharmaceuticalsApproved
Andriol
AAuxilium
Approved
Recombinant Human Erythropoietin
AmgenApproved
Ozempic
Novo NordiskPhase 3
Eldecalcitol
SShanghai Jiao Tong University Affiliated Sixth People's Hospital
Approved
Deca-Durabolin
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Bimagrumab
NovartisPhase 2
Comparator: Pbo
Merck & Co.Phase 2
REGN1033
RegeneronPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sarcopenia1 trial
Huangjing Yangji Formula Combined With Resistance Training for Sarcopenia
Not yet recruiting·WWangjing Hospital, China Academy of Chinese Medical Sciences·N/A·NCT07321535·106 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details